Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till årsstämma torsdagen den 25 juni 2020, kl. 16:00 på Tvistevägen 48C i Umeå. Aktieägare som önskar delta i stämman ska vara införd i aktieboken per dagen för stämman. Föranmälan senast måndagen den 22 juni 2019 per e-post till investor@lipum.se/sv. Ladda ned kallelsen här »
What effect has elevated levels of our target molecule on human blood? Together with our partner Immuneed we will increase our understanding. Another step towards a novel treatment of inflammatory diseases.
At last our fully humanised antibody and lead candidate SOL-116 will be traveling soon. The production development at Abzena proceeds successfully and according to plan. Downstream processing and quality control have been done and SOL-116 is on its way to Umeå. An enthusiastic team is waiting impatiently to continue with further studies.
Dr Kristian Sandberg is an associate professor in immunology and an experienced leader in the pharmaceutical industry’s research and development. Sandberg has over 20 years’ experience from AstraZeneca in various functions within R&D, primarily with project leader responsibilities. He has experiences from the development of both protein and conventional small molecule based drugs from concept [...]
In March Lipum will attend Bio-Europe Spring, Europe's largest partnership conference for the biotechnology industry. Meet us there! Visit site: https://informaconnect.com/bioeurope-spring/
Aktieägarna i Lipum AB, org. nr. 556813-5999, kallas härmed till extra bolagsstämma tisdagen den 3 mars 2020, kl. 13:00 på Tvistevägen 48C i Umeå. Styrelsen föreslår att Dr Kristian Sandberg väljs som ordinarie styrelseledamot i Lipum AB. Ladda ned kallelse här »
After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and that will provide access of non-GMP and GMP material during 2020. That will enable toxicity studies and start of clinical trials as planned during 2021. [...]
Press release November 29, 2019 Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric immunology at the University of [...]
“How we selected our CMO partner for cell line and production development of Lipum´s lead candidate drug SOL-116” […]
Life Science industry leaders, financing experts and qualified investors gather in Lund. Welcome to meet us at Biostock Life Science Summit, october 23th-24th. […]